Secondary immunodeficiency in lymphoproliferative malignancies

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Secondary immunodeficiencies arise from diseases like hematological malignancies (MM, CLL) and treatments (immunosuppressants, biologics).
• Infections are a primary cause of illness and death in MM and CLL patients, exacerbated by cumulative immunosuppression from relapses and salvage therapies.
• Understanding the multifactorial pathogenesis of immune deficiency in lymphoproliferative malignancies is crucial for effective management.

Purpose of the Study:

• To provide an overview of the immunology underlying secondary immunodeficiency in MM and CLL.
• To discuss infectious complications associated with these hematological malignancies.
• To review evidence for prophylactic replacement immunoglobulin therapy in antibody failure patients with MM and CLL.

Main Methods:

• Literature review and synthesis of current knowledge on secondary immunodeficiency.
• Analysis of disease- and treatment-related factors contributing to immune compromise.
• Evaluation of evidence supporting immunoglobulin replacement therapy.

Main Results:

• Secondary immunodeficiencies in MM and CLL patients significantly elevate infection risk.
• Supportive care, including vaccination and prophylaxis, is vital.
• Prophylactic replacement immunoglobulin shows promise for patients with antibody failure.

Conclusions:

• Secondary immunodeficiency in MM and CLL is complex, driven by both the disease and its treatments.
• Early intervention with supportive care and consideration of immunoglobulin replacement are key to mitigating infectious risks.
• Further research into optimal prophylactic strategies is warranted.